Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?
Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients
Answer from: at Academic Institution
Yes and no. It is clear that you can cure patients with pediatric HL without the use of brentuximab vedotin. While I believe it is safe and effective, if it is not covered by insurance, I would not advocate for its use in low and intermediate risk pediatric patients.However, for HR pediatric patient...
Sign in or Register to read more